about akston
process
pipeline
news
careers
contact
NEWS
9 February 2021
Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC
Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC
16 January 2021
Disrupting Insulin and IGF Receptor Function in Cancer
Disrupting Insulin and IGF Receptor Function in Cancer
5 January 2021
Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452
Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452
1 September 2020
TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452
TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452
22 July 2020
Akston Biosciences Receives $2.5M Milestone Payment
Akston Biosciences Receives $2.5M Milestone Payment
27 May 2020
Akston Biosciences Awarded NIDDK Phase IIb Grant
Akston Biosciences Awarded NIDDK Phase IIb Grant
9 April 2020
Akston Biosciences Completes Series E Preferred Stock Financing
Akston Biosciences Completes Series E Preferred Stock Financing
15 February 2020
Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth
Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth
2 August 2019
Akston Biosciences Completes Licensing and Supply Agreement with Dechra Pharmaceuticals PLC
Akston Biosciences Completes Licensing and Supply Agreement with Dechra Pharmaceuticals PLC
24 July 2019
Helmsley Charitable Trust and Akston Biosciences Corporation Extend Partnership
Helmsley Charitable Trust and Akston Biosciences Corporation Extend Partnership
1
9
10
11
